Diagonal Bio

Kolgjini Stables, led by Lutfi Kolgjini, is a prominent player both in harness racing and horse breeding. The facility, located near Lund holds up to 180 horses. The large number of horses in proximity makes rapid virus detection especially critical to prevent the spread of infections within the stables. A rapid diagnostic method allows breeders to promptly isolate infected horses, proactively safeguarding their animals' health and minimising the risk of transmission.

The pilot test at Kolgjini Stables is part of Diagonal Bio's ongoing strategy to commercialise the LAMPlify® solution aimed at horse breeders seeking solutions to prevent the spreading of viruses. The result of this pilot test will help ensure that LAMPlify® effectively meets the specific needs of the horse breeding and racing industry.

“Fast and accurate virus detection can make a huge difference in protecting our horses and ensuring a safe environment at our facility. We look forward to evaluating how the LAMPlify® platform can support proactive measures to protect our horses from potential risks,” - Dante Kolgjini, harness racer at Kolgjini Stables with three V75 victories in 2023.

“Just as with competitive horses, breeding involves significant investments and requires dedication, expertise, and a strong commitment to animal welfare. We are proud to collaborate with esteemed facilities like Kolgjini Stables in their efforts to uphold these high standards,” - Karin Wehlin, CEO of Diagonal Bio AB (publ).

This press release contains inside information that Diagonal Bio AB (publ) is required to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication on November 13, 2024, at 15:00 CET.

For additional information about, please contact:

Karin Wehlin, CEO

Phone: +46 703 052488

E-mail: kw@diagonalbio.com

Certified Adviser

Svensk Kapitalmarknadsgranskning AB

E-mail: ca@skmg.se

About Diagonal Bio

Diagonal Bio AB was founded in 2020 and is a Swedish biotechnology company with headquarters and offices in Lund. The Company develops the PANVIRAL® platform to detect and diagnose small sections of pathogen genomes, for example viruses, bacteria and fungi. The Company was founded with the goal of reducing human suffering by revolutionising global diagnostics of pathogen-borne diseases with proprietary technology. Diagonal Bio's patented technology can also be used for the less regulated market segments via LAMPlify®.